MAP3K7 and prostate cancer: For example, by acting as a tumor suppressor, TAK1 has been shown to negatively associated with tumor progression in several human cancers including prostate cancer (Huang et al., 2021), hepatocellular carcinoma (HCC) (Tan et al., 2020; Wang et al., 2021), cervical cancer (Guan et al., 2017), and certain blood cancers (Guo et al., 2019).